Yüklüyor......
Combined Treatment with Stattic and Docetaxel Alters the Bax/Bcl-2 Gene Expression Ratio in Human Prostate Cancer Cells
Docetaxel, recognized as a stabilizing microtubule agent, is frequently administrated as a first line treatment for prostate cancers. Due to high side effects of monotherapy, however, combinations with novel adjuvants have emerged as an alternative strategy in cancer therapy protocols. Here, we inve...
Kaydedildi:
| Yayımlandı: | Asian Pac J Cancer Prev |
|---|---|
| Asıl Yazarlar: | , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
West Asia Organization for Cancer Prevention
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5454715/ https://ncbi.nlm.nih.gov/pubmed/28032735 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.22034/APJCP.2016.17.11.5031 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|